A positive 67Ga scan at the end of therapy is rarely seen in patients with Hodgkin's disease and should be considered a manifestation of gross residual disease. However, a negative 67Ga scan after therapy had a significantly lower predictive value in patients with stage III to IV disease compared with stage I to II disease. The predictive value of 67Ga scans, as well as newer imaging studies, should be analyzed according to pretreatment stage.

p-gp is frequently expressed in patients with untreated breast cancer, with p-gp-positive patients being at significantly greater risk for disease recurrence. p-gp appears to be a useful prognostic factor in breast cancer and could potentially help guide management.

No abstract

Duplex-directed manual occlusion (DDMO) has emerged as a first line treatment in selected cases of iatrogenic pseudoaneurysms related to interventional and therapeutic femoral artery cannulations. Early recurrences after successful closure of femoral false aneurysms (FFA) are described in the literature; however, very little long-term follow-up data are available. Therefore, the authors reviewed their experience with DDMO of 45 FFAs between February 1991 and December 1994. Follow-up was arranged to assess the durability of this noninvasive procedure. DDMO was unsuccessful in three of 45 FFAs (6.6%). Symptomatic recurrences of two FFAs were documented by repeat duplex ultrasound at 7 and 20 days post DDMO. Repeat DDMO was successful on one whereas the other required surgical closure. One additional patient experienced persistent groin discomfort despite successful DDMO necessitating surgical evacuation of a large hematoma. Four patients died during the follow-up period. Thirty-five patients with 36 FFAs remained eligible for long-term eval uation. Three were lost to follow-up and six patients were interviewed by phone and denied symptoms suggestive of recurrence but refused further follow-up. Twenty-six patients with a history of 24 FFAs underwent repeat duplex scans. No recurrent FFAs were identified with mean follow-up of 17.5 months (range 1-35). The authors conclude that DDMO is a safe, effective, and durable treatment of iatrogenic femoral false aneurysms.